

## DAFTAR PUSTAKA

- Abrahamsson, P., Swedberg, K., Borer, J.S., Böhm, M., Kober, L., Komajda, M., et al., 2013. Risk following hospitalization in stable chronic systolic heart failure. *Eur. J. Heart Fail.* 15: 885–891.
- Adams, K.F., Gheorghiade, M., Uretsky, B.F., Young, J.B., Ahmed, S., Tomasko, L., et al., 1997. Patients with mild heart failure worsen during withdrawal from digoxin therapy. *J. Am. Coll. Cardiol.* 30: 42–48.
- Ahmed, M.I., Mujib, M., Desai, R. V., Feller, M.A., Daniel, C., Aban, I.B., et al., 2012. Outcomes in younger and older adults with chronic advanced systolic heart failure: A propensity-matched study. *Int. J. Cardiol.* 154: 128–133.
- Alwi, I., 2018. Diagnosis dan tatalaksana gagal jantung. Perkumpulan Informasi dan Penerbitan Interna, Jakarta.
- Appiah, D., Schreiner, P.J., Demerath, E.W., Loehr, L.R., Chang, P.P., Folsom, A.R., 2016. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis. *J. Am. Heart Assoc.* 5: 1–10.
- Arora, S., Patel, P., Lahewala, S., Patel, N., Patel, N.J., Thakore, K., et al., 2017. Etiologies, Trends, and Predictors of 30-Day Readmission in Patients With Heart Failure. *Am. J. Cardiol.* 119: 760–769.
- Baker, D.W., 2002. Prevention of heart failure. *Curr. Opin. Cardiol.* 21: 510–516.
- Bhagat, A.A., Greene, S.J., Vaduganathan, M., Fonarow, G.C., Butler, J., 2019. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. *JACC Hear. Fail.* 7: 1–12.
- Blouin, J., Dragomir, A., Fredette, M., Ste-Marie, L.-G., Fernandes, J.C., Perreault, S., 2009. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. *Osteoporos Int* 20: 1571–1581.
- Bonow, R.O., Louis, S., Mann, D.L., Libby, P., 2011. Heart Disease Braunwald ' S, Elsevier.
- Bourge, R.C., Fleg, J.L., Fonarow, G.C., Cleland, J.G.F., McMurray, J.J.V., Van Veldhuisen, D.J., et al., 2013. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. *Am. J. Med.* 126: 701–708.
- Bristow, M.R., 2010.  $\beta$ -Adrenergic Receptor Blockade in Chronic Heart Failure Michael R. Bristow *Circulation* 2000;101;558-569 558–569.

- Bristow, M.R., 1997. Mechanism of action of beta-blocking agents in heart failure. *Am. J. Cardiol.* 80: 26L–40L.
- Buie, V.C., Maria F., O., Carol J., D., Golosinskiy, A., 2006. National Hospital Discharge Survey: 2006 Annual Summary. *Vital Health Stat.* 13. 1.
- Chang, L.L., Xu, H., DeVore, A.D., Matsouaka, R.A., Yancy, C.W., Fonarow, G.C., et al., 2018. Timing of postdischarge follow-up and medication adherence among patients with heart failure. *J. Am. Heart Assoc.* 7.
- Chatterjee, S., Biondi-Zoccai, G., Abbate, A., D’Ascenzo, F., Castagno, D., Van Tassell, B., et al., 2013. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. *BMJ* 346: f55.
- Chaturvedi, N., 1997. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. *Lancet* 349: 1787–1792.
- Cheng, R., Cox, M., Neely, M.L., Heidenreich, P.A., Bhatt, D.L., Eapen, Z.J., et al., 2014. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. *Am. Heart J.* 168: 721–730.e3.
- Cleland, J.G.F.F., Tendera, M., Adamus, J., Freemantle, N., Polonski, L., Taylor, J., 2006. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur. Heart J.* 27: 2338–2345.
- Cohn, J.N., Tognoni, G., Investigators, for the V.H.F.T., 2001. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. *N Engl J Med* 345:1667–1.
- Coyle, J.D., Gardner, S.F., White, C.M., 2004. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. *Ann. Pharmacother.* 38: 1731–1738.
- Cramer, J.A., Roy, A., Burrell, A., Fairchild, C.J., Fuldeore, M.J., Ollendorf, D.A., et al., 2008. Medication compliance and persistence: Terminology and definitions. *Value Heal.* 11: 44–47.
- Curtis, L.H., Mi, X., Qualls, L.G., Check, D.K., Hammill, B.G., Hammill, S.C., et al., 2013. Heart failure: Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. *Am. Heart J.* 165: 979–986.e1.
- Curtis, L.H., Mi, X., Qualls, L.G., Check, D.K., Hammill, B.G., Hammill, S.C., et al., 2008. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. *Am. Heart J.* 165: 979–986.e1.

- Davies, M.K., Gibbs, C.R., Lip, G.Y., 2000. ABC of heart failure. *BMJ* 320: 297–300.
- Deeka, H., Skouri, H., Nouredine, S., 2016. Readmission rates and related factors in heart failure patients: A study in Lebanon. *Coll. 2016;23(1)61-8*. 23(1):61–8.
- Deschaseaux, C., Mcsharry, M., Hudson, E., 2016. Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis 22: 561–71.
- Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J.V., Ponikowski, P., Poole-Wilson, P.A., et al., 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008†. *Eur. J. Heart Fail.* 10: 933–989.
- Dupont, W., Plummer, W., 1990. “Power and Sample Size Calculations: A Review and Computer Program.” *Control. Clin. Trials* 11:116-28.
- Ebong, I.A., Watson, K.E., Jr, D.C.G., A., D., Bluemke, Srikanthan, P., et al., 2014. Age at Menopause and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis 21: 585–591.
- Esposti, L.D., Saragoni, S., Batacchi, P., Geppetti, P., Buda, S., Esposti, E.D., 2010. Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years. *Clin. Outcomes Res.* 2: 113–120.
- Febrinasari, R.P., Martohusodo, B.I., Kristin, E., Nindrea, R.D., Dwiprahasto, I., 2019. Comparing The Effect of Angiotensin-Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers in Heart Failure Patients with Type 2 Diabetes Mellitus : A Systematic Review (Inpress). Yogyakarta.
- Feingold KR, B, A., Boyce A, et al., 2018. Medication Induced Changes in Lipid and Lipoproteins. [WWW Document]. *South Dartmouth MDText.com, Inc.*
- Felker, G.M., Teerlink, J.R., 2015. 24 - Diagnosis and Management of Acute Heart Failure, Tenth Edit. ed, Braunwald’s Heart Disease, 10/e. Elsevier Inc.
- Ferdinand, K.C., 2007. African American Heart Failure Trial: Role of Endothelial Dysfunction and Heart Failure in African Americans. *Am. J. Cardiol.* 99: 2–5.
- Ferrari, R., 2005. Angiotensin-converting enzyme inhibition in cardiovascular disease: Evidence with perindopril. *Expert Rev. Cardiovasc. Ther.* 3: 15–29.
- Fitch, K., Pelizzari, P.M., Pyenson, B., 2015. The High Cost of Heart Failure for the Medicare Population: An Actuarial Cost Analysis. Milliman Client Report, Commissioned by Novartis Pharmaceuticals. February 2, 2015.
- Flather, M.D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., et al., 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. *Lancet* 355: 1575–1581.

- Garg, R., Yusuf, S., 1995. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure Dr Yusuf has received monetary compensation for speaking engagements from several pharmaceutical companies, including some . *Jama* 273: 1450–1456.
- Gerber, Y., Weston, S.A., Margaret M. Redfield Alanna M. Chamberlain PhD, Sheila M. Manemann, MPH, Ruoxiang Jiang, BS, Jill M. Killian, BS, and Véronique L. Roger, MD, M., Department, Orleans, N., 2016. A Contemporary Appraisal of the Heart Failure Epidemic in Olmsted County, Minnesota, 2000-2010 5: 1–8.
- Gheorghiade, M., van Veldhuisen, D.J., Colucci, W.S., 2006. Contemporary Use of Digoxin in the Management of Cardiovascular Disorders. *Circulation* 113: 2556–2564.
- Gislason, G.H., Rasmussen, J.N., Abildstrom, S.Z., Schramm, T.K., Hansen, M.L., Buch, P., et al., 2007. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. *Circulation* 116: 737–744.
- Givertz, M.M., 2001. Manipulation of the Renin-Angiotensin System. *Circulation* 104: e14–e18.
- Gjesing, A., Schou, M., Torp-Pedersen, C., Køber, L., Gustafsson, F., Hildebrandt, P., et al., 2013. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. *Eur. J. Heart Fail.* 15: 671–678.
- Göhler, A., Geisler, B.P., Manne, J.M., Kosiborod, M., Zhang, Z., Weintraub, W.S., et al., 2009. Utility estimates for decision-analytic modeling in chronic heart failure - Health states based on New York Heart Association classes and number of rehospitalizations. *Value Heal.* 12: 185–187.
- Grover, S. a, Coupal, L., Lowensteyn, I., 2008. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate? *Can. J. Cardiol.* 24: 261–266.
- Haehling, S. Von, Lainscak, M., Springer, J., Anker, S.D., 2009. Pharmacology & Therapeutics Cardiac cachexia : A systematic overview. *Pharmacol. Ther.* 121: 227–252.
- Hall, M.J., Levant, S., DeFrances, C.J., 2012. Hospitalization for congestive heart failure: United States, 2000-2010. *NCHS Data Brief* 1–8.
- Hall, P.S., Nah, G., Howard, B. V., Lewis, C.E., Allison, M.A., Sarto, G.E., et al., 2017. Reproductive Factors and Incidence of Heart Failure Hospitalization in the Women’s Health Initiative. *J. Am. Coll. Cardiol.* 69: 2517–2526.
- Hassan, N.B., Hasanah, C.I., Foong, K., Naing, L., Awang, R., Ismail, S.B., et al., 2006. Identification of psychosocial factors of noncompliance in hypertensive

- patients. *J. Hum. Hypertens.* 20: 23–29.
- Heran, B., Vm, M., Bassett, K., Rs, T., Jm, W., 2012. Angiotensin receptor blockers for heart failure ( Review ). *Cochrane sytematic Rev.* 1–80.
- Holdford, D. a., 2010. Pharmacoeconomics: From Theory to Practice, Advances in Colloid and Interface Science.
- Investigators, C., 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 353: 9–13.
- Iorga, A., Cunningham, C.M., Moazeni, S., Ruffenach, G., Umar, S., Eghbali, M., 2017. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biol. Sex Differ.* 8: 33.
- Jalnapurkar, S., Zhao, X., Heidenreich, P.A., Bhatt, D.L., Smith, E.E., DeVore, A.D., et al., 2018. A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. *Am. Heart J.* 200: 127–133.
- Jessup, M., Brujena, S., 2013. Heart Failure, 2nd ed. CRC Press, New York.
- Juarez, D.T., Williams, A.E., Chen, C., Daida, Y.G., Tanaka, S.K., Trinacty, C.M., et al., 2015. Factors affecting medication adherence trajectories for patients with heart failure. *Am. J. Manag. Care* 21: e197-205.
- Kalogeropoulos, A.P., Georgiopoulou, V. V, Butler, J., 2016. 17 Epidemiology of Heart Failure, Third Edit. ed, Heart Failure: A Companion to Braunwald's Heart Disease. Elsevier Inc.
- Kapeliou, C.J., Kaldara, E., Ntalianis, A., Nana, E., Pantsios, C., Repasos, E., et al., 2016. Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation : A randomized study. *Int. J. Cardiol.* 177: 690–692.
- Kayibanda, J.F., Girouard, C., Grégoire, J.P., Demers, E., Moisan, J., 2018. Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users? *Res. Soc. Adm. Pharm.* 14: 915–920.
- Kemenkes RI, 2018. Laporan Nasional Riskesdas 2018, Badan Penelitian dan Pengembangan Kesehatan. Kementerian kesehatan RI, Jakarta.
- Kemenkes RI, 2013. Riset Kesehatan Dasar 306.
- KemenKes RI, 2015. Nomor HK.02.02/MENKES/523/2015 tentang Formularium Nasional.
- Konstam, M.A., Neaton, J.D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F.A., et al., 2009. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-

blind trial. *Lancet* 374: 1840–1848.

- Konstam, M.A., Poole-Wilson, P.A., Dickstein, K., Drexler, H., Justice, S.J., Komajda, M., et al., 2008. Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. *Eur. J. Heart Fail.* 10: 899–906.
- Kristensen, S.L., Jhund, P.S., Køber, L., Preiss, D., Kjekshus, J., McKelvie, R.S., et al., 2015. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. *Eur. J. Heart Fail.* 17: 169–76.
- Krum, H., Mohacsi, P., Katus, H.A., Tendera, M., Rouleau, J.L., Fowler, M.B., et al., 2006. Are  $\beta$ -blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. *Am. Heart J.* 151: 55–61.
- Lachaine, J., Beauchemin, C., Ramos, E., 2011. Use, tolerability and compliance of spironolactone in the treatment of heart failure. *BMC Clin. Pharmacol.* 11: 4.
- Lee, K.K., Shilane, D., Hlatky, M.A., Yang, J., Steimle, A.E., Go, A.S., 2013. Effectiveness and safety of spironolactone for systolic heart failure. *Am. J. Cardiol.* 112: 1427–1432.
- Lind, M., Bounias, I., Olsson, M., Gudbjörnsdottir, S., Svensson, A.M., Rosengren, A., 2011. Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: An observational study. *Lancet* 378: 140–146.
- Loehr, L.R., Rosamond, W.D., Chang, P.P., Folsom, A.R., Chambless, L.E., 2008. Heart Failure Incidence and Survival (from the Atherosclerosis Risk in Communities Study). *Am. J. Cardiol.* 101: 1016–1022.
- López, B., González, A., Beaumont, J., Querejeta, R., Larman, M., Díez, J., 2007. Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure. *J. Am. Coll. Cardiol.* 50: 859–867.
- Macdonald, M. r., Eurich, dean t., Majumdar, sumit r., Lewsey, james d., Bhagra, S., 2010. Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure : 33.
- Maggioni, A.P., Anand, I., Gottlieb, S.O., Latini, R., Tognoni, G., Cohn, J.N., 2002. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. *J. Am. Coll. Cardiol.* 40: 1414–1421.
- Mahmoudpour, S.H., Asselbergs, F.W., Souverein, P.C., de Boer, A., Maitland-van der Zee, A.H., 2018. Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study. *Br. J. Clin. Pharmacol.* 84: 2365–2372.

- Makani, H., Messerli, F.H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R.S., et al., 2012. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. *Am. J. Cardiol.* 110: 383–391.
- Mann, D.L., 2015. 25 - Management of Patients with Heart Failure with Reduced Ejection Fraction, Tenth Edit. ed, Braunwald's Heart Disease, 10/e. Elsevier Inc.
- Margolis, J., Gerber, R.A., Roberts, C., Gheorghiade, M., 2010. Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure. *Am. J. Ther.* 17: 446–454.
- Mariyono, H., Santoso, A., 2007. Gagal jantung. *J. Penyakit Dalam* 8: 85–94.
- McMurray, J., Ostergren, J., Swedberg, K., Granger, C., Held, P., Michelson, et al., 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet.* 2003 Sep 6;362(.
- McMurray, J.J. V, Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al., 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. *Eur. Heart J.* 33: 1787–847.
- Mentz, R.J., Kelly, J.P., von Lueder, T.G., Voors, A.A., Lam, C.S.P., Cowie, M.R., et al., 2014. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. *J. Am. Coll. Cardiol.* 64: 2281–2293.
- Merit-hf Study, G., 2001. Effect of metoprolol CR / XL in chronic heart failure : Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure 353: 2001–2007.
- Meyer, M.R., Barton, M., 2016. Estrogens and Coronary Artery Disease: New Clinical Perspectives, 1st ed, Advances in Pharmacology. Elsevier Inc.
- Mirkin, K.A., Enomoto, L.M., Caputo, G.M., Hollenbeak, C.S., 2017. Risk factors for 30-day readmission in patients with congestive heart failure. *Hear. Lung J. Acute Crit. Care* 46: 357–362.
- Mockler, M., O'Loughlin, C., Murphy, N., Ryder, M., Conlon, C., McDonald, K.M., et al., 2009. Causes and Consequences of Nonpersistence With Heart Failure Medication. *Am. J. Cardiol.* 103: 834–838.
- Mosterd, A., Hoes, A.W., 2007. Clinical epidemiology of heart failure. *Heart* 93: 1137–1146.
- Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M.,

- et al., 2016. AHA Statistical Update Heart Disease and Stroke Statistics — 2016 Update A Report From the American Heart Association WRITING Group Members.
- Muszbek, N., Brixner, D., Benedict, A., Keskinaslan, A., Khan, Z.M., 2008. The economic consequences of noncompliance in cardiovascular disease and related conditions: A literature review. *Int. J. Clin. Pract.* 62: 338–351.
- Naik, S.D., Freudenberger, R.S., 2007. Beta-blocker contraindications: Are there patients or situations where use is inappropriate? *Curr. Heart Fail. Rep.* 4: 93–98.
- NICE, 2010. Chronic heart failure in adults: management. *Nice.Org.Uk/Guidance/Cg108*.
- Nichols, G.A., Reynolds, K., Kimes, T.M., Rosales, A.G., Chan, W.W., 2015. Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. *Am. J. Cardiol.* 116: 1088–1092.
- Nurmainah, 2014. Persistensi penggunaan antihipertensi sebagai prediktor kejadian penyakit kardiovaskular dan biaya pada pasien hipertensi peserta asuransi PT Askes (Persero) di RSUD Panembahan Senopati Bantul. (Disertasi) Universitas Gadjah Mada.
- Packer, M., Antonopoulos, G. V., Berlin, J.A., Chittams, J., Konstam, M.A., Udelson, J.E., 2001. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. *Am. Heart J.* 141: 899–907.
- Packer, M., Poole-wilson, P. a, Armstrong, P.W., Cleland, J.G.F., Horowitz, J.D., Massie, B.M., et al., 1999. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure 2312–2318.
- PERKI, 2015a. Pedoman Tatalaksana Gagal Jantung, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Jakarta.
- PERKI, 2015b. Pedoman tatalaksana sindrom koroner akut. *Pedoman Tatalaksan Sindr. Koroner Akut* 88.
- Pitt, B., Segal, R., Martinez, F.A., Meurers, G., Cowley, A.J., Thomas, I., et al., 1997. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 349: 747–752.
- Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., et al., 1999. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. *N Engl J Med.* 341: 709–17.

- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., et al., 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.* 37: 2129-2200m.
- Pribadi, W.F., 2015. Analisis biaya terapi kombinasi diuretik dengan ace- inhibitor terhadap terapi diuretik tanpa ace- inhibitor pada pasien gagal jantung peserta askes. Thesis. Universitas Gadjah Mada.
- Rahman I, A, A., W., 2015. Relationship between age at natural menopause and risk of heart failure. *Menopause* 22(1):12–6.
- Remme, W.J., Torp-Pedersen, C., Cleland, J.G.F., Poole-Wilson, P.A., Metra, M., Komajda, M., et al., 2007. Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. Results From COMET. *J. Am. Coll. Cardiol.* 49: 963–971.
- Roger, V.L., 2010. The heart failure epidemic. *Int. J. Environ. Res. Public Health* 7: 1807–1830.
- Rogers, J.K., McMurray, J.J. V, Pocock, S.J., Zannad, F., Krum, H., Van Veldhuisen, D.J., et al., 2012. Eplerenone in patients with systolic heart failure and mild symptoms: Analysis of repeat hospitalizations. *Circulation* 126: 2317–2323.
- Ruppar, T.M., Cooper, P.S., Mehr, D.R., Delgado, J.M., Dunbar-Jacob, J.M., 2016. Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. *J. Am. Heart Assoc.* 5: 1–19.
- Sanchez, L., 2005. Chapter 1 . Pharmacoeconomics : Principles , Methods , and Applications. *McGraw Hill, New York* 6: 1–46.
- Sastroasmoro, S., 2014. Dasar-dasar Metodologi Penelitian Klinis. Sagung Seto, Jakarta.
- Semigran, M., Shin, J.T., 2012. Heart Failure, 2nd editio. ed. CRC Press, New York.
- Sikka, R., Xia, F., Aubert, R.E., 2005. Estimating medication persistency using administrative claims data. *Am. J. Manag. Care* 11: 449–457.
- Silavanich, V., Nathisuwan, S., Phrommintikul, A., Permsuwan, U., 2018. Relationship of medication adherence and quality of life among heart failure patients. *Hear. Lung* 000: 1–6.
- Sokol, M.C., McGuigan, K.A., Verbrugge, R.R., Epstein, R.S., 2005. Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost. *Med. Care* 43: 521–530.
- Solomon, S.D., Claggett, B., Desai, A.S., Packer, M., Zile, M., Swedberg, K., et al., 2016. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction:

- The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (. *Circ. Hear. Fail.* 9: 1–6.
- SOLVD Investigators, 1991. Effect of enalapril on survival in patients with reduced LEVF and CHF. *N. Engl. J. Med.* 325: 293–302.
- Stålhammar, J., Stern, L., Linder, R., Sherman, S., Parikh, R., Ariely, R., et al., 2012. Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients. *J. Med. Econ.* 15: 938–46.
- Steinberg, B.A., Zhao, X., Heidenreich, P.A., Peterson, E.D., Bhatt, D.L., Cannon, C.P., et al., 2012. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. *Circulation* 126: 65–75.
- Sulaiman, S.A.S, Alomar, M.J., and Strauch, C., 2009. Variability in Antihypertensive Drug Therapy and Compliance: Results from a Random Survey in the United Arab Emirates Syed Azhar Syed Sulaiman , 2 Muaed Jamal Alomar and 2 Claire Caroline Strauch Department of Clinical Pharmacy , Faculty of Pharmacy and 4: 38–47.
- Sulita, H., 2011. Analisa Biaya dan variabel yang berpengaruh terhadap biaya pengobatan pasien gagal jantung rawat inap di RSUD Sleman Yogyakarta periode 2009. Universitas Gadjah Mada Yogyakarta.
- Sun, S.X., Ye, X., Lee, K.Y., Dupclay, L., Plauschinat, C., 2008. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. *Clin. Ther.* 30: 2217–2227.
- Sunita, P., Pattanayak, S., 2011. Phytoestrogens in postmenopausal indications: A theoretical perspective. *Pharmacogn. Rev.* 5: 41.
- Tarride, J.-E., Lim, M., DesMeules, M., Luo, W., Burke, N., O'Reilly, D., et al., 2009. A review of the cost of cardiovascular disease. *Can. J. Cardiol.* 25: e195–e202.
- Tsao, C.W., Lyass, A., Enserro, D., Larson, M.G., Ho, J.E., Kizer, J.R., et al., 2018. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. *JACC Hear. Fail.* 6: 678–685.
- Tsutamoto, T., Wada, A., Maeda, K., Mabuchi, N., Hayashi, M., Tsutsui, T., et al., 2001. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *J. Am. Coll. Cardiol.* 37: 1228–1233.
- Tung, Y.-C., Huang, Y.-C., Wu, L.-S., Chang, C.-J., Chu, P.-H., 2017. Medication compliance and clinical outcomes of fixed-dose combinations vs free

- combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment. *J. Clin. Hypertens.* 1–7.
- Viana, M., 2014. Medication Adherence to Specific. *J. Manag. Care Spec. Pharm. JMCP* 20: 1018–1026.
- WHO, 2018. Anatomical Therapeutic Chemical Classification System (ATC Code) [WWW Document].
- WHO, 2003. Adherence to Long Term Therapies World Health Organization 2003.
- Widagdo, F., Karim, D., Novayellinda, R., 2014. Faktor-faktor yang berhubungan dengan kejadian rawat inap ulang dirumah sakit pada pasien chf.
- Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., et al., 2010. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. *Eur. Heart J.* 31: 2369–429.
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Colvin, M.M., et al., 2017a. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. *J. Am. Coll. Cardiol.* 70: 776–803.
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Colvin, M.M., et al., 2016. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinic, Circulation.
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., et al., 2017b. 2017 ACC / AHA / HFSA Focused Update of the 2013 ACCF / AHA Guideline for the Management of Heart Failure.
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Drazner, M.H., et al., 2013. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. *J. Am. Coll. Cardiol.* 62: 1495–1539.
- Yanti, N., 2019. Analisis faktor-faktor risiko pasien gagal jantung kronik dengan hipertensi terhadap kejadian rawat inap ulang dan biaya rawat di RSUD Dr.Soedarso periode 2015-2017. Thesis. Universitas Gadjah Mada.